UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 286

Sortiert nach

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

Open forum infectious diseases, 2019-03, Vol.6 (Supplement_1), p.S79-S94

2019

Volltextzugriff (PDF)

Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry

Clinical infectious diseases, 2009-06, Vol.48 (12), p.1695-1703

2009

Volltextzugriff (PDF)

Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination

International journal of antimicrobial agents, 2020-01, Vol.55 (1), p.105799-105799, Article 105799

2020

Volltextzugriff (PDF)

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program

Open forum infectious diseases, 2019-03, Vol.6 (Supplement_1), p.S47-S53

2019

Volltextzugriff (PDF)

T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis

Future microbiology, 2016-01, Vol.11 (1), p.103-117

2016

Volltextzugriff (PDF)

Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.561-566

2011

Volltextzugriff (PDF)

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

International journal of antimicrobial agents, 2011-07, Vol.38 (1), p.65-69

2011

Volltextzugriff (PDF)

In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

Antimicrobial Agents and Chemotherapy, 2013-02, Vol.57 (2), p.1065-1068

2013

Volltextzugriff (PDF)

Analysis of Candida auris fungemia at a single facility in Kenya

International journal of infectious diseases, 2019-08, Vol.85, p.182-187

2019

Volltextzugriff (PDF)

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Journal of global antimicrobial resistance., 2021-09, Vol.26, p.117-127

2021

Volltextzugriff (PDF)

Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates

Antimicrobial Agents and Chemotherapy, 2014-01, Vol.58 (1), p.577-580

2014

Volltextzugriff (PDF)

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

International journal of infectious diseases, 2021-11, Vol.112, p.321-326

2021

Volltextzugriff (PDF)

Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression

Journal of global antimicrobial resistance., 2022-06, Vol.29, p.371-377

2022

Volltextzugriff (PDF)

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

The Brazilian journal of infectious diseases, 2017-11, Vol.21 (6), p.627-637

2017

Volltextzugriff (PDF)

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Journal of global antimicrobial resistance., 2021-12, Vol.27, p.337-351

2021

Volltextzugriff (PDF)

Has Antifungal Susceptibility Testing Come of Age?

Clinical infectious diseases, 2002-10, Vol.35 (8), p.982-989

2002

Volltextzugriff (PDF)

Risk Factors for Candidal Bloodstream Infections in Surgical Intensive Care Unit Patients: The NEMIS Prospective Multicenter Study

Clinical infectious diseases, 2001-07, Vol.33 (2), p.177-186

2001

Volltextzugriff (PDF)

Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015–2017) Pseudomonas aeruginosa isolates from a global surveillance programme

Journal of global antimicrobial resistance., 2020-06, Vol.21, p.60-64

2020

Volltextzugriff (PDF)

In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

Antimicrobial Agents and Chemotherapy, 2011-11, Vol.55 (11), p.5155-5158

2011

Volltextzugriff (PDF)

Nosocomial Bloodstream Infections in United States Hospitals: A Three-Year Analysis

Clinical infectious diseases, 1999-08, Vol.29 (2), p.239-244

1999

Volltextzugriff (PDF)

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Journal of antimicrobial chemotherapy, 2017-05, Vol.72 (5), p.1386-1395

2017

Volltextzugriff (PDF)

Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014–2019)

Journal of global antimicrobial resistance., 2020-12, Vol.23, p.278-283

2020

Volltextzugriff (PDF)

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)

Diagnostic microbiology and infectious disease, 2016-06, Vol.85 (2), p.200-204

2016

Volltextzugriff (PDF)

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International journal of antimicrobial agents, 2018-08, Vol.52 (2), p.144-150

2018

Volltextzugriff (PDF)

Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals

Clinical infectious diseases, 2004-01, Vol.38 (1), p.78-85

2004

Volltextzugriff (PDF)

1 – 25 von 286

Suche als RSS-Feed

Aktive Filter

ThemaMycology

ThemaInfectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(283)
Mit Volltextzugriff
(254)

Publikationsform

Artikel
(285)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(269)
Science & Technology
(269)
Microbiology
(216)
Humans
(199)
Biological And Medical Sciences
(178)
Medical Sciences
(161)
Microbial Sensitivity Tests
(112)
Pharmacology. Drug Treatments
(81)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(80)
Anti-Bacterial Agents - Pharmacology
(66)
Immunology
(59)
Infections
(57)
Antibacterial Agents
(56)
Epidemiology
(55)
Pharmacology & Pharmacy
(52)
Fundamental And Applied Biological Sciences. Psychology
(48)
Male
(44)
Bacteriology
(42)
Female
(40)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry

Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program

T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis

Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

Analysis of Candida auris fungemia at a single facility in Kenya

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Has Antifungal Susceptibility Testing Come of Age?

Risk Factors for Candidal Bloodstream Infections in Surgical Intensive Care Unit Patients: The NEMIS Prospective Multicenter Study

Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015–2017) Pseudomonas aeruginosa isolates from a global surveillance programme

In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

Nosocomial Bloodstream Infections in United States Hospitals: A Three-Year Analysis

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014–2019)

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals

Aktive Filter

Suchergebnisse filtern